A randomized phase II study of concomitant trastuzumab, bevacizumab with paclitaxel versus trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab and paclitaxel at progression as first-line treatment of patients with metastatic breast cancer with HER2-neu overexpression.

Trial Profile

A randomized phase II study of concomitant trastuzumab, bevacizumab with paclitaxel versus trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab and paclitaxel at progression as first-line treatment of patients with metastatic breast cancer with HER2-neu overexpression.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms HAT
  • Most Recent Events

    • 17 Jun 2016 Status changed from active, no longer recruiting to completed, as per the results published in the Cancer
    • 17 Jun 2016 Results published in the Cancer
    • 31 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top